Background. We explored the establishment of abnormal blood-brain barrier (BBB) permeability and its relationship to neuropathogenesis during primary human immunodeficiency virus (HIV) infection by evaluating the cerebrospinal fluid (CSF) to serum albumin quotient (Q Alb ) in patients with primary HIV infection. We also analyzed effects of initiating combination antiretroviral therapy (cART).
Chronic exposure to human immunodeficiency virus (HIV) can lead to neurological complications, with one third of untreated individuals with advanced AIDS developing HIV-associated dementia [1, 2] , a syndrome of severe cognitive, motor, and behavioral disturbances primarily associated with subcortical atrophy [3] . Although the incidence of HIV-associated dementia has significantly decreased with the advent of combination antiretroviral therapy (cART), a milder spectrum of neurocognitive deficits persists despite treatment [1, 2, 4] . As this persisting impairment may at least in part represent irreversible alterations of central nervous system (CNS) integrity accrued before the initiation of cART, investigative efforts have been drawn toward elucidating neuropathogenesis during the early stages of HIV neuroinvasion and examining the effects of early cART on these processes.
Primary HIV infection (PHI) refers to the first phase of infection, from the time of transmission up to 12 months after transmission [5] . HIV infiltrates the CNS during PHI [6] [7] [8] , as indicated by the presence of HIV RNA in the cerebrospinal fluid (CSF) compartment, even in the absence of neurological symptoms [1, [8] [9] [10] [11] . CNS immune activation accompanies this viral invasion, as reflected by elevations in the CSF white blood cell count and the soluble CSF biomarkers neopterin (reflecting macrophage activation) and CXCL-10/IP-10 (a lymphocyte chemokine) and by T-lymphocyte activation in CSF [1, [12] [13] [14] [15] . Furthermore, markers of immune activation may reflect the degree of viral load and neurocognitive impairment [16] . Magnetic resonance spectroscopy (MRS), a noninvasive quantitative MR technique that measures alterations in cerebral metabolite levels, demonstrates that inflammatory cerebral metabolites are elevated in acute HIV infection (ie, the period before antibody seroconversion) and longitudinally increased over time in PHI before cART initiation [1, 17, 18] . Thus, crucial processes during the primary phase of viral infection may underlie the initiation of HIV-associated CNS injury.
It is speculated that increased blood-brain barrier (BBB) permeability is a critical contributor to HIV neuropathogenesis because disruption of this regulatory interface facilitates CNS infiltration of potentially harmful substances from the periphery, resulting in compounding viral entry and susceptibility to the inflammatory assault of immune cells [19, 20] . To exert its neurological effects, HIV-1 and/or its viral products must first traverse the BBB. Although data suggest that, at this initial stage, HIV is transported to the CNS via trafficking of infected immune cells across a largely intact BBB, increased permeability of the BBB has been implicated in the progression of HIV neurological dysfunction [19, [21] [22] [23] [24] . The ratio of the albumin level in the CSF to that in serum (also known as the CSF to serum albumin concentration quotient [Q Alb ]) is the best established fluid marker for BBB permeability [25] . Albumin is synthesized exclusively in the liver and is largely excluded from the CSF. Upon deregulation of the neurovascular unit and sequential loss of tight junctions, BBB permeability to albumin increases, resulting in an increased Q Alb .
In this study, we aimed to elucidate the natural history of BBB permeability during PHI and to determine whether changes in permeability, if present, were associated with biomarkers of neuropathogenesis. Additionally, we sought to determine whether BBB permeability was responsive to cART initiated during PHI. These results provide novel understanding of the changes to the brain microenvironment that begin during initial HIV infection and the persistence of these alterations in the setting of early, virologically suppressive cART.
MATERIALS AND METHODS

Study Design
Individuals with PHI were recruited into prospective longitudinal studies of CNS HIV in Gothenburg, Sweden, and San Francisco, California, between 1986 and 2014, as previously described [9] . Participants were enrolled within the first year after HIV transmission, as confirmed by the standard serologic testing algorithm for recent HIV seroconversion (STAHRS) [26] , and all but 3 were ART naive. A subset began cART at variable times during follow-up for reasons outside of the study. None of the participants had a prior neurological disease history. A history of substance abuse was not an exclusion criterion, but no participants reported same-day substance abuse, which would have led to censoring of data. The date of HIV transmission was approximated as 14 days before the onset of seroconversion symptoms, when present [27] ; otherwise, it was approximated as midway between the dates of the last negative and first positive result of an enzyme immunoassay [28] . HIVuninfected volunteers were recruited from the San Francisco community and had no history of neurological conditions or active systemic diseases.
Ethics
The study protocol was approved by the institutional review board of each institution involved. All study participants gave written consent.
Data Collection and Laboratory Analysis
CSF and blood specimens were obtained and neuropsychological testing and MRS were performed at each visit as previously described [23, 29] . Study visits were scheduled at baseline, 6 weeks, and every 6 months thereafter, although there was participant variation in the timing and duration of follow-up.
CSF neurofilament light chain (NFL) levels were measured with the NF-light enzyme-linked immunosorbent assay kit (UmanDiagnostics, Umeå, Sweden), a sensitive immunoassay [21] , with reference values for the upper limit of normal (ULN) of 380 ng/L (for individuals aged 18-29 years), 560 ng/L (for those aged 30-39 years), 890 ng/L (for those aged 40-59 years), and 1850 ng/L (for those aged >59 years) [21] . CSF and plasma albumin levels were measured by nephelometry (Behring Nephelometer Analyzer; Behringwerke, Marburg, Germany). Q Alb was calculated as the ratio of the CSF level of albumin, in milligrams/liter, to the plasma level of albumin, in grams/liter [22] . Upper limits of normal were based on previously established values of <6.8 for ages <45 years and <10.2 for ages >45 years [30] . CSF WBCs, lymphocytes, total protein, and HIV RNA were measured as previously described [9] . Viral loads of <50 copies/mL were assigned a value of 49 copies/mL (1.69 on log 10 scale).
Neuropsychological performance was determined through the appraisal of gross and fine motor skills, processing speed, executive function, learning, and verbal memory, using a battery of 11 tests. Performance was summarized as an aggregate total z score and a brief NPZ-4 score (including grooved pegboard, digit symbol, finger tapping, and timed gait).
Brain magnetic resonance imaging (MRI)/MRS were performed at the San Francisco site only. MRS data were processed and analyzed with the spectral fitting software siTools, which uses a parametric model of known (metabolites) and modeled (macromolecules) spectral components to fit all resonances and nonparametric parameters to the baseline value. Metabolite disturbances can indicate neuropathology, including inflammation and injury. The ratio of the peak area under the curve for the metabolite N-acetylaspartate to the peak area under the curve for creatine-containing metabolites (NAA:Cr) is a putative marker of neuronal viability and number. We focused spectral acquisition on the parietal gray matter, as we have previously identified metabolite abnormalities in this region during PHI [17, 23] .
Statistical Analysis
Baseline characteristics were summarized as frequencies for categorical variables and median values and interquartile ranges for continuous variables. Nonparametric, χ 2 , and Fisher exact tests were used for group comparisons. The mixed-effects model was used to analyze longitudinal change of Q Alb after transmission. This model includes both fixed and random effects in the same analysis, allowing for variation in the number and interval of participant follow-up visits. Baseline age was included as a fixed-effect covariate in the model. To account for a possible nonlinear trajectory of Q Alb over time, a quadratic term (t 2 ) was included as a fixed-effect covariate. The model included a personal intercept for each participant as a random effect, allowing the baseline Q Alb to vary for each participant. As log-transformed results were comparable to non-log-transformed analysis, the latter results are reported. The plot of fitted group mean Q Alb trend was superposed on observed individual data. Between-subject and within-subject correlation were evaluated using the Bland and Altman method [31, 32] .
Statistical analyses were performed using the SPSS 23.0 statistical package (IBM, Armonk, NY). The significance level was set as a P value of < .05 (2 sided).
RESULTS
Study Participant Characteristics
A total of 106 participants with PHI fulfilled the inclusion criteria and had available Q Alb values. Nine participants experienced clinically overt neurological disorders during seroconversion: there were 2 cases of meningitis, 5 of headache with photophobia, 2 of brachial neuritis, and 1 each of Guillain-Barre syndrome, facial palsy, and encephalitis. Total visits ranged from 1 to 13, with a median of 2, and the maximum follow-up duration was 3572 days, with a median of 50 days. The majority of participants were infected with HIV subtype B [9] .
The baseline characteristics of participants with PHI and uninfected controls are presented in Table 1 . The median duration of HIV infection in participants with PHI was 91 days; the plasma viral load during PHI was 1.8 log 10 greater relative to that in the CSF compartment. As compared to the HIVuninfected participants, the PHI cohort had a higher percentage of males and was younger. As expected, participants with PHI had a lower CD4 + T-cell count, an elevated CD8 + T-cell count, and a decreased ratio of CD4 + T cells to CD8 + T cells. As previously reported, CSF white blood cell counts were elevated in the PHI group, as well as CSF levels of neopterin, a marker of macrophage activation. Despite the younger age, participants with PHI had levels of NFL and equivalent CSF total protein-2 parameters that increase in level with normal aging-that were greater than those for the uninfected group, [21, 33, 34] .
BBB Permeability at Baseline
At baseline, the mean age-adjusted Q Alb was elevated in the PHI cohort (5.9; 95% confidence interval [CI], 5.5-6.3) as compared to that for controls (5.0; 95% CI, 4.4-5.6; P = .02).
On the basis of previously published reference values [30] , the baseline Q Alb was above the age-specific ULN in 22 participants with PHI (21%), hereafter referred to as the "high baseline Q Alb subgroup. " The remaining 84 participants with PHI with baseline Q Alb values below the ULN are referred to hereafter as the "normal baseline Q Alb subgroup. " The baseline clinical characteristics of these 2 subgroups are summarized in Table 2 . Four of seventeen participants (24%) in the high baseline Q Alb subgroup had neurosymptomatic seroconversion, compared with 8 of 64 (13%) in the normal baseline Q Alb subgroup, although the difference was statistically insignificant. An elevated NFL level, CSF total protein level, CSF neopterin (but not blood neopterin) level, and CD8 + T-cell count and a decreased ratio of plasma to CSF levels of HIV RNA were found in the high baseline Q Alb subgroup as compared to the normal baseline Q Alb subgroup.
Longitudinal BBB Permeability in PHI Before cART Initiation
The individual Q Alb trajectories for all participants in the PHI group over the duration of the study before cART initiation are plotted in Figure 1 . A mixed-model analysis to evaluate the natural history of BBB integrity in the overall PHI group before cART initiation did not reveal a significant change in Q Alb over time (-0.000436/day; P = .092). and reached a plateau quickly (quadratic time effect P = .004). These results indicated the heterogeneous time effect in the 2 subgroups.
Correlation of BBB Integrity With Markers of Neuropathogenesis
To further evaluate the implications of elevated Q Alb , correlations between Q Alb and markers of neuronal health were evaluated in pre-cART study intervals ( Figure 3 ). Partial correlation coefficients were calculated to correct for the confounding effects of age, as the Q Alb and NFL level both directly correlate with age. The Q Alb demonstrated a strong positive correlation with the NFL level, a marker of active neuronal injury, upon cross-sectional analysis at baseline (r = 0.497; P < .001) and longitudinally, with both between-participant (r = 0.555; P < .001) and within-participant (r = 0.523; P = .001) analysis. Q Alb inversely correlated with NAA:Cr, a cerebral metabolite biomarker of neuronal health, upon cross-sectional analysis at baseline (r = -0.352; P = .015) and longitudinally, with between-participant analysis (r = -0.387; P = .008) but not within-participant analysis (r = 0.218; P = .125). MRS was performed at a median interval of 114 days after infection. Q Alb did not correlate with composite z scores (total z or NPZ4) of neuropsychological testing at baseline or in longitudinal analysis (data not shown).
Characteristics of cART Recipients
Fifty-eight participants with PHI initiated a cART regimen during study follow-up, although 1 participant was excluded because of virologic failure (defined as 2 consecutive plasma samples with an HIV RNA load of >50 copies/mL after 6 months of ART). Treatment regimens were heterogeneous, consisting of 10 integrase-based, 25 protease-based, and 22 nonnucleoside reverse transcriptase inhibitor-based regimens with 19 distinct combinations. cART was initiated at a median interval of 225 days after infection, with a median duration of follow-up during cART of 402 days. Table 3 compares the cross-sectional laboratory parameters before (ie, during the last visit before treatment initiation) and after (ie, during the last visit of the study) cART initiation in those who initiated cART. There was improvement in most parameters after approximately a year of cART, with suppression of plasma and CSF HIV RNA levels to the lower limit of detection by polymerase chain reaction (P < .001), increased CD4 + T-cell counts (P < .001), decreased WBC counts (P < .001), and decreased blood and CSF neopterin levels (P < .001). In this comparison, the NFL level and albumin ratio did not significantly change with cART (640 vs 670 ng/L [P = .911] and 5.18 vs 5.09 [P = .851], respectively).
Longitudinal History of BBB Integrity Following cART Initiation
A mixed-model analysis was performed to assess the longitudinal trajectory of Q Alb over 13 months of cART ( Figure 4 ). Three participants were recruited into the cohort after already having initiated cART (for 29, 27, and 19 days) and thus were included in the linear mixed model (n = 60) but are excluded from the group described in Table 3 . As cART was initiated at a median interval of 225 days after infection (t = 0 in Figure 4 ), this time point corresponded with the linear portion shown in Figure 2 , in which the quadratic changes of the normal baseline subgroup are resolving and reaching a set point. Thus, the initial analysis was performed with the total group of cART recipients, rather than separating cART recipients into the high and normal baseline Q Alb subgroups. There was no significant change detected in Q Alb over the median duration (ie, >1 year) of cART (slope, −0.00369/month; P = .174). With group stratification, the high baseline Q Alb subgroup (n = 7) demonstrated no significant change in Q Alb over time (P = .783). The low baseline subgroup (n = 53) demonstrated a slope of effectively 0 (slope, 0.00008/ month; P = .004), similar to the pre-cART plateau.
DISCUSSION
In this study, we analyzed the natural history of BBB permeability and the influence of early cART during primary HIV infection. We show that albumin ratio is mildly elevated in participants with PHI, compared with that for uninfected controls, when correcting for age. This correction is relevant given that BBB permeability increases with normal aging [35] and may explain why previous studies have not reported abnormalities in BBB permeability during PHI when compared to controls,
given that most studies of PHI enroll young patients. That being said, we have previously identified moderate elevation of the albumin ratio during PHI [9, 36] and in participants with chronic HIV infection who are cART naive and neuroasymptomatic [9] . Similarly, Li et al have reported a strong association between matrix metalloproteinases-enzymatic surrogate markers of BBB permeability-and neurocognitive status in PHI [37] . The novelty of this study is our finding that BBB permeability undergoes dynamic changes during PHI, even within days of transmission. Two distinct trajectories were noted for the PHI cohort when analysis was stratified by baseline albumin ratio. Those with a normal baseline albumin ratio (ie, a ratio below the ULN) showed a mild initial increase that plateaued within the first 1000 days of infection. Despite the initial rise, the Q Alb remained well below the ULN. As will be discussed below, it may be that there is an element of subclinical injury associated with this mild rise. The subgroup with a high baseline albumin ratio demonstrated a marked decline in the albumin ratio within the first 1000 days of infection. Presumably an early rise in albumin ratio occurred immediately following infection, before participant recruitment, and began to resolve during the follow up. Notably, the subgroup with a higher baseline albumin ratio was characterized by a higher percentage of neurosymptomatic seroconversion, elevated levels of CSF markers of axonal injury and immune activation, and a higher ratio of CSF to plasma levels of HIV RNA. These findings suggest that a subgroup of participants with PHI is susceptible to marked BBB disruption, which persists even beyond 1000 days after infection, and is associated with signs of increased CNS involvement. Factors that predispose individuals to one trajectory versus the other warrant further investigation.
Previous studies have expounded on the association of the albumin ratio with biomarkers of CNS inflammation and injury [20] . We confirm that, during PHI, the albumin ratio correlates strongly with the level of the axonal injury marker, NFL [23] , and are the first to demonstrate that it inversely correlates with the metabolic marker of neuronal health, NAA:Cr. NFL is a sensitive marker of active neuronal damage, and its levels correlate with the severity of this damage [38] [39] [40] . We have previously shown NFL to be the most sensitive neuronal biomarker for assessing HIV neurodegeneration, as it can detect subclinical injury in neuroasymptomatic individuals, even during PHI [36, 41] . As disease progresses, it is also associated with overt clinical neurological disease, thus reflecting not only structural changes, but also functional changes [38] . Although NFL is not specific for HIV neurodegeneration [36, 39] , comorbid neurological conditions were excluded from the study onset. Similar to Q Alb , the NFL level was elevated during PHI, although it was below the ULN (<560 ng/L), possibly indicating subclinical damage, which may explain the lack of correlation with NPZ-4 test results. In line with this conclusion, we have previously shown a lack of correlation between NFL levels and NPZ-4 results during PHI, despite showing moderate elevations when compared to findings for uninfected controls [23, 36] . Similar to the utility of the NFL level as a biomarker of early subclinical injury, MRS has been shown to detect early HIV-associated neuropathogenesis before detection of conventional MRI changes [42] . In a recent study, subjects with chronic HIV infection who have cognitive deficits were shown to have reduced glutamate and NAA levels in several brain regions, most pronounced in the parietal gray matter [43] . Here, we extend that finding to PHI.
Once we demonstrated that BBB permeability was altered in PHI and associated with markers of neuronal pathology, we assessed whether early cART could remediate these changes. Surprisingly, the effect of cART on BBB permeability has not been intensely evaluated. In an unpublished study, Crozier et al observed the gradual diminishment of the median albumin ratio (from 6.48 to 6.09) in 16 neuroasymptomatic participants with chronic HIV infection after 200 days of cART [44] ; thus, although BBB integrity improved over time with cART, a return to baseline or near baseline function may take years. In contrast, Abdulle et al reported no significant reduction in BBB permeability after 2 years of cART in 38 neuroasymptomatic participants [45] . Importantly, the median baseline albumin ratio among participants in the study by Crozier et al was greater than that of participants in the study by Abdulle et al (6.48 vs 4.45), potentially contributing to the discrepancy in the cohort response to cART. In our study, cART, initiated at a median interval of 225 days after infection, was effective in suppressing CSF and plasma HIV RNA, suggesting medication compliance and effectiveness. Notably, the inflammatory marker neopterin improved to the upper level of normal limits both in the plasma and CSF. Despite this systemic (including CNS) suppression of viral replication and inflammation, the NFL level and albumin ratio were unchanged. The pre-cART measurement of the albumin ratio was comparable to that of the age-matched uninfected controls and thus may indicate that the acute changes of the albumin ratio in the high baseline Q Alb subgroup had largely resolved and reached a level near baseline once cART was initiated at a median interval of 225 days after infection. On the other hand, although the NFL level was below the age-specific ULN (<840 pg/mL), it was significantly elevated as compared to that for uninfected controls and the baseline PHI cohort, given only a marginal age difference. There is a gradual normalization of the NFL level following axonal injury, which is unlikely to persist for over a year [46] . Thus, this persistently elevated level of NFL may reflect continued subclinical injury despite cART and what appears to be a largely normal albumin ratio.
We hypothesize that perhaps (1) the initially altered BBB permeability initiated CNS injury, which persists despite resolution of BBB integrity; (2) the mechanism of injury is independent of BBB integrity; or (3) BBB permeability is mildly elevated and has not fully returned to baseline, resulting in persisting neuronal injury. Alternatively, it is possible that, despite the large sample size, we still have insufficient power to detect a significant change in the NFL level and Q Alb after cART initiation. Further studies are necessary to elucidate the possible explanation. Notably, a previous study showed normalization of the ratio of CD4 + to CD8 + T cells during PHI only when cART was initiated within 6 months after transmission [47] . Furthermore, in a cohort of individuals who started treatment during acute HIV infection, the CSF NFL level was not elevated at baseline nor after 6 and 24 months of cART [48] . The effects of earlier cART intervention on normalization of the albumin ratio should be investigated.
This study has several limitations. Q Alb is affected by many factors not accounted for in this study, including body weight and smoking [35] . Although cholesterol and other cardiovascular risk factors were not routinely screened, none of the participants had a known history of clinically apparent cardiovascular disease, such as coronary artery disease, peripheral vascular disease, or stroke. One participant, in the low baseline group, had a known diagnosis of diabetes mellitus type 2. Abuse of substances such as cocaine has been shown to at least transiently increase BBB permeability [49] ; thus, misreporting of ongoing drug use or long-term effects of previous drug use cannot be discounted as confounding factors. Furthermore, given the observational nature of this study, cART regimens were heterogeneous, which may result in distinct effects on the BBB.
BBB permeability undergoes a dynamic process during PHI, demonstrating acute changes within days. We identified 2 subgroups of participants with PHI with different albumin ratio trajectories: one with a presumed acute increase and gradual improvement over the course of infection and a second with a mild initial increase. BBB permeability correlated with markers of neuropathogenesis. Initiation of cART in the first year of infection did not significantly alter BBB permeability in our study. Further investigations should test the effects of earlier cART initiation, especially in individuals with signs of early BBB disruption. 
